Search the Newsreel

Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages

Design Therapeutics, Inc. (NASDAQ:DSGN) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $16.50. The stock recently opened at $14.33, trading above its 50-day and 200-day moving averages, and institutional investors own over 56% of the …

Design Therapeutics, Inc. $DSGN Shares Purchased by Sei Investments Co.

Sei Investments Co. significantly increased its stake in Design Therapeutics, Inc. (NASDAQ:DSGN) by 152.6% in the first quarter, now holding 133,203 shares valued at approximately $1.42 million. Institutional investors collectively own 56.64% of the company. Despite reporting a quarterly EPS of negative $0.32, beating …

Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Design Therapeutics Inc (DSGN), noting its current earnings forecast score is 8.86, ranking 47 out of 387 in its industry. Analysts have set an average price target of $12.50, with a majority recommending a "Buy" for the …

Renaissance Technologies LLC Buys 121,100 Shares of Design Therapeutics, Inc. $DSGN

Renaissance Technologies LLC increased its stake in Design Therapeutics, Inc. (NASDAQ:DSGN) by 42.2% in the first quarter, purchasing an additional 121,100 shares, bringing its total holdings to 408,200 shares valued at approximately $4.34 million. Other institutional investors have also adjusted their positions in the …

Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22

Craig-Hallum has reiterated its Buy rating for Design Therapeutics (DSGN.US) and maintained its target price at $22. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Design Therapeutics Q2 Net Loss Narrows

Design Therapeutics reported a narrowed net loss for the second quarter, although it did not provide specific figures in the provided document. The company's financial performance indicates an improvement in its loss compared to the previous period.

Design Therapeutics posts Q2 loss, updates clinical trials

Design Therapeutics Inc. reported a net loss of $20.2 million for Q2 2026, or $0.32 per share, with total cash and investments at $207.4 million. The company updated its RESTORE-FA trial for Friedreich ataxia, specifying endogenous blood FXN protein percent change as the primary …

Design Therapeutics (NASDAQ:DSGN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

Design Therapeutics reported its second-quarter 2026 financial results and provided updates on its clinical programs. The company highlighted progress in its RESTORE-FA trial for Friedreich ataxia, initiating patient dosing for DT-818 in myotonic dystrophy type 1, and advancing preclinical work for Huntington's disease. Design …

Design Therapeutics (NASDAQ: DSGN) highlights FA data alongside Q2 loss

DSGN|Design Therapeutics Inc|Price:11.860|Chg%:-0.020

This article provides a comprehensive stock analysis of Design Therapeutics Inc (DSGN) by TradingKey. It highlights the company's relatively weak fundamentals but high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Despite institutional confidence and a strong …

Design Therapeutics Inc (DSGN) Institutional Confidence

Design Therapeutics Inc (DSGN) has an institutional shareholding score of 5.00, placing it 132nd out of 385 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently decreased by 8.26% quarter-over-quarter to 61.89%. Steven Cohen is the largest institutional shareholder, holding …

Design Therapeutics Inc (DSGN) Balance Sheet

Design Therapeutics Inc (DSGN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Design Therapeutics Inc (DSGN), detailing various financial metrics related to volatility, drawdown, and liquidity. Key figures include a Beta vs S&P 500 index of 1.66, a 240-Day Volatility of +84.43%, and a 5-year maximum drawdown of +92.22%. …

DSGN|Design Therapeutics Inc|Price:11.955|Chg%:+0.175

Design Therapeutics Inc. (DSGN) is a biotechnology company focused on developing gene-targeted chimera therapeutic candidates for diseases caused by inherited nucleotide repeat expansion mutations. The company's stock is currently priced at $11.89 with a market cap of $718.13M, showing high growth potential despite relatively …

We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

This article analyzes Design Therapeutics' cash burn rate, concluding that despite a high burn, the company has enough cash to last for over two years. The analysis considers the company's current cash and short-term investments against its cash burn from operations and investing activities. …

Design Therapeutics (DSGN) Q1 2026 earnings summary

Design Therapeutics (DSGN) reported its Q1 2026 earnings, detailing advancement in four GeneTAC® molecule programs for severe monogenic disorders, including Friedreich Ataxia (FA), Fuchs Endothelial Corneal Dystrophy (FECD), Myotonic Dystrophy Type 1 (DM1), and Huntington's Disease (HD). The company's lead FA candidate, DT-216P2, progressed …

Design Therapeutics (DSGN) Jefferies London Healthcare Conference 2024 Summary

Design Therapeutics (DSGN) presented at the Jefferies London Healthcare Conference 2024, highlighting its strategic vision for pioneering small molecule genomic medicines for monogenic diseases. The company detailed pipeline progress, including plans to advance programs for Friedreich ataxia and Fuchs endothelial corneal dystrophy into clinical …

Design Therapeutics (DSGN) Proxy filing Summary

Design Therapeutics (DSGN) has summarized its proxy filing, detailing an Annual Meeting scheduled for June 9, 2026. Shareholders will vote on electing a Class II director and ratifying Ernst & Young LLP as the independent auditor for fiscal year 2026, with proxy materials available …

Design Therapeutics begins DM1 trial for DT-818, aims at genetic cause

Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Smaller-than-Expected Loss Lifts Shares 5.28% - Earnings Volatility Report

DSGN Forecast — Price Target — Prediction for 2027

DSGN Q1 2026 Earnings: Narrowed Loss Beats Expectations as Pipeline Advances - Revenue Warning Signal

Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May - Design Therapeutics (NASDAQ:DSGN), F

Earnings call transcript: Design Therapeutics beats Q1 2026 EPS expectations

We Think Design Therapeutics (NASDAQ:DSGN) Can Afford To Drive Business Growth

Clinical-Stage Biotech Design Therapeutics Set for Major Jefferies Healthcare Conference Presentation

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

What is the current Price Target and Forecast for Design Therapeutics (DSGN)

Design Therapeutics, Inc. (DSGN) Stock Price, News, Quote & History